Novartis and IBM Watson are teaming up in a “ground-breaking collaboration” that aims to marry machine learning with real-world data to improve outcomes in advanced breast cancer. More: Novartis links with IBM Watson Health on breast cancer Source: News
read moreCost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss. More: NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis Source:
read moreNovartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo. More: BMS, Novartis to test Mekinist/Opdivo combo Source: News
read moreUK biotech Glythera has announced the launch of a £1 million Innovate UK grant-funded project to develop next-generation antibody drug conjugates (ADCs) for difficult-to-treat tumours. More: Glythera launches Innovate UK-funded ADC project Source: News
read moreJapan’s Sawai is following the path tread by other drugmakers with big plans for the U.S., establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation. More: Japan's Sawai gets U.S. production with B deal for Upsher-Smith generics Source:
read moreThe annual ASCO meeting often throws new light on old drugs—and old dealmaking. This year, it’s last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—that doesn’t look so impressive anymore, thanks to data rolled out over the weekend.
read more© 1994 - 2026 B.M. Pharmaceuticals